Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
Cultured rat hepatocytes have been used extensively to study the mechanisms of chemically induced peroxisome proliferation. Hepatocytes from nonrodent species have been used on a limited scale to study interspecies differences in the response. Because of their importance in pharmaceutical safety assessment, we have developed a model to study the response of beagle dog and rhesus monkey hepatocytes to peroxisome proliferators. Treatment of the hepatocytes with peroxisome proliferators was begun after 20 hr in culture and continued for 72 hr. Untreated rat, dog, and monkey hepatocytes retained 62, 42, and 43% of their initial (20 hr) peroxisomal beta-oxidation activity throughout 92 hr of culture. Ciprofibrate, bezafibrate, and LY171883 caused a dose-related increase in beta-oxidation in rat hepatocytes to a maximum of 10-, 8-, and 5-fold, respectively. In dog and monkey hepatocytes the increases in beta-oxidation were less than 2-fold. Peroxisome morphology in dog and monkey hepatocytes appeared to be unchanged by the drugs. Morphometric analysis in monkey hepatocytes showed no increase in peroxisome volume fraction in response to the chemicals. Treatment of dog and monkey hepatocytes with dexamethasone and glucagon during the final 24 hr in culture caused a 4- to 6-fold increase in tyrosine aminotransferase activity. This induction is characteristic of the in vivo response. The small increase in beta-oxidation reflects the relative insensitivity of the dog and monkey liver to peroxisome proliferators in vivo rather than a loss of sensitivity during culture. Cultured hepatocytes from beagle dog and rhesus monkey may provide a model for studying the mechanisms underlying the interspecies differences. Such information would help clarify the relevance of rodent data in human risk assessment.
Foxworthy
P S
PS
Lilly Research Laboratories, Eli Lilly and Company, Greenfield, Indiana 46140.
White
S L
SL
Hoover
D M
DM
Eacho
P I
PI
D000098:Acetophenones / Q000494:pharmacology*; D000818:Animals; D012898:Autacoids / Q000037:antagonists & inhibitors*; D001393:Azoles / Q000494:pharmacology*; D001629:Bezafibrate / Q000494:pharmacology*; D002478:Cells, Cultured; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D058607:Fibric Acids; D005934:Glucagon / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D008099:Liver / Q000166:cytology / Q000187:drug effects*; D008297:Male; D008830:Microbodies / Q000187:drug effects; D008854:Microscopy, Electron; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D051381:Rats; D013777:Tetrazoles / Q000494:pharmacology*; D014444:Tyrosine Transaminase / Q000032:analysis
D000098:Acetophenones; D012898:Autacoids; D001393:Azoles; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D013777:Tetrazoles; D009243:NAD; D002995:Clofibric Acid; D003907:Dexamethasone; C044660:LY 171883; D005934:Glucagon; D014444:Tyrosine Transaminase; C019304:ciprofibrate; D002994:Clofibrate; D001629:Bezafibrate